| components_charts_RevenueChart_14 | Rigel Pharmaceuticals components_charts_RevenueChart_8 | Rigel Pharmaceuticals components_charts_RevenueChart_10 | Rigel Pharmaceuticals components_charts_RevenueChart_9 |
|---|---|---|---|
| 2030e | 362.1 number_format_mio undefined | 134.54 number_format_mio undefined | 73.36 number_format_mio undefined |
| 2029e | 324.81 number_format_mio undefined | 115.26 number_format_mio undefined | 84.99 number_format_mio undefined |
| 2028e | 294.72 number_format_mio undefined | 92.06 number_format_mio undefined | 71.57 number_format_mio undefined |
| 2027e | 262.55 number_format_mio undefined | 70.15 number_format_mio undefined | 61.73 number_format_mio undefined |
| 2026e | 232.5 number_format_mio undefined | 48.36 number_format_mio undefined | 42.08 number_format_mio undefined |
| 2025e | 196.01 number_format_mio undefined | 18.31 number_format_mio undefined | 15.3 number_format_mio undefined |
| 2024e | 151.97 number_format_mio undefined | -8.92 number_format_mio undefined | -11.48 number_format_mio undefined |
| 2023 | 116.88 number_format_mio undefined | -20.49 number_format_mio undefined | -25.09 number_format_mio undefined |
| 2022 | 120.2 number_format_mio undefined | -54.3 number_format_mio undefined | -58.6 number_format_mio undefined |
| 2021 | 149.2 number_format_mio undefined | -9 number_format_mio undefined | -17.9 number_format_mio undefined |
| 2020 | 108.6 number_format_mio undefined | -29 number_format_mio undefined | -29.7 number_format_mio undefined |
| 2019 | 59.3 number_format_mio undefined | -69.1 number_format_mio undefined | -66.9 number_format_mio undefined |
| 2018 | 44.5 number_format_mio undefined | -72.7 number_format_mio undefined | -70.5 number_format_mio undefined |
| 2017 | 4.5 number_format_mio undefined | -79.6 number_format_mio undefined | -78 number_format_mio undefined |
| 2016 | 20.4 number_format_mio undefined | -64.4 number_format_mio undefined | -69.2 number_format_mio undefined |
| 2015 | 28.9 number_format_mio undefined | -51.7 number_format_mio undefined | -51.5 number_format_mio undefined |
| 2014 | 8.3 number_format_mio undefined | -81.9 number_format_mio undefined | -90.9 number_format_mio undefined |
| 2013 | 7.2 number_format_mio undefined | -87.8 number_format_mio undefined | -89 number_format_mio undefined |
| 2012 | 2.3 number_format_mio undefined | -99.4 number_format_mio undefined | -98.8 number_format_mio undefined |
| 2011 | 4.8 number_format_mio undefined | -86.4 number_format_mio undefined | -86 number_format_mio undefined |
| 2010 | 125 number_format_mio undefined | 35.3 number_format_mio undefined | 37.9 number_format_mio undefined |
| 2009 | 800,000 undefined | -110.9 number_format_mio undefined | -111.5 number_format_mio undefined |
| 2008 | 0 undefined | -136.7 number_format_mio undefined | -132.3 number_format_mio undefined |
| 2007 | 12.6 number_format_mio undefined | -79.5 number_format_mio undefined | -74.3 number_format_mio undefined |
| 2006 | 33.5 number_format_mio undefined | -43 number_format_mio undefined | -37.6 number_format_mio undefined |
| 2005 | 16.5 number_format_mio undefined | -47.9 number_format_mio undefined | -45.3 number_format_mio undefined |
| 2004 | 4.7 number_format_mio undefined | -56.9 number_format_mio undefined | -56.3 number_format_mio undefined |
| components_charts_RevenueChart_8 | components_charts_RevenueChart_10 | components_charts_RevenueChart_9 | |
|---|---|---|---|
| 2004 | 4.7 number_format_mio USD | -56.9 number_format_mio USD | -56.3 number_format_mio USD |
| 2005 | 16.5 number_format_mio USD | -47.9 number_format_mio USD | -45.3 number_format_mio USD |
| 2006 | 33.5 number_format_mio USD | -43 number_format_mio USD | -37.6 number_format_mio USD |
| 2007 | 12.6 number_format_mio USD | -79.5 number_format_mio USD | -74.3 number_format_mio USD |
| 2008 | 0 USD | -136.7 number_format_mio USD | -132.3 number_format_mio USD |
| 2009 | 800,000 USD | -110.9 number_format_mio USD | -111.5 number_format_mio USD |
| 2010 | 125 number_format_mio USD | 35.3 number_format_mio USD | 37.9 number_format_mio USD |
| 2011 | 4.8 number_format_mio USD | -86.4 number_format_mio USD | -86 number_format_mio USD |
| 2012 | 2.3 number_format_mio USD | -99.4 number_format_mio USD | -98.8 number_format_mio USD |
| 2013 | 7.2 number_format_mio USD | -87.8 number_format_mio USD | -89 number_format_mio USD |
| 2014 | 8.3 number_format_mio USD | -81.9 number_format_mio USD | -90.9 number_format_mio USD |
| 2015 | 28.9 number_format_mio USD | -51.7 number_format_mio USD | -51.5 number_format_mio USD |
| 2016 | 20.4 number_format_mio USD | -64.4 number_format_mio USD | -69.2 number_format_mio USD |
| 2017 | 4.5 number_format_mio USD | -79.6 number_format_mio USD | -78 number_format_mio USD |
| 2018 | 44.5 number_format_mio USD | -72.7 number_format_mio USD | -70.5 number_format_mio USD |
| 2019 | 59.3 number_format_mio USD | -69.1 number_format_mio USD | -66.9 number_format_mio USD |
| 2020 | 108.6 number_format_mio USD | -29 number_format_mio USD | -29.7 number_format_mio USD |
| 2021 | 149.2 number_format_mio USD | -9 number_format_mio USD | -17.9 number_format_mio USD |
| 2022 | 120.2 number_format_mio USD | -54.3 number_format_mio USD | -58.6 number_format_mio USD |
| 2023 | 116.88 number_format_mio USD | -20.49 number_format_mio USD | -25.09 number_format_mio USD |
| 2024e | 151.97 number_format_mio USD | -8.92 number_format_mio USD | -11.48 number_format_mio USD |
| 2025e | 196.01 number_format_mio USD | 18.31 number_format_mio USD | 15.3 number_format_mio USD |
| 2026e | 232.5 number_format_mio USD | 48.36 number_format_mio USD | 42.08 number_format_mio USD |
| 2027e | 262.55 number_format_mio USD | 70.15 number_format_mio USD | 61.73 number_format_mio USD |
| 2028e | 294.72 number_format_mio USD | 92.06 number_format_mio USD | 71.57 number_format_mio USD |
| 2029e | 324.81 number_format_mio USD | 115.26 number_format_mio USD | 84.99 number_format_mio USD |
| 2030e | 362.1 number_format_mio USD | 134.54 number_format_mio USD | 73.36 number_format_mio USD |
components_StockTable_20
components_StockTable_21
components_StockTable_17
components_StockTable_18
components_StockTable_19
| Rigel Pharmaceuticals components_charts_MarginsChart_15 | Rigel Pharmaceuticals components_charts_MarginsChart_16 | Rigel Pharmaceuticals components_charts_MarginsChart_17 | Rigel Pharmaceuticals components_charts_MarginsChart_16 |
|---|---|---|---|
| 2030e | 93.92 % | 37.16 % | 20.26 % |
| 2029e | 93.92 % | 35.49 % | 26.16 % |
| 2028e | 93.92 % | 31.24 % | 24.28 % |
| 2027e | 93.92 % | 26.72 % | 23.51 % |
| 2026e | 93.92 % | 20.8 % | 18.1 % |
| 2025e | 93.92 % | 9.34 % | 7.8 % |
| 2024e | 93.92 % | -5.87 % | -7.55 % |
| 2023 | 93.92 % | -17.53 % | -21.47 % |
| 2022 | 98.59 % | -45.17 % | -48.75 % |
| 2021 | 99.33 % | -6.03 % | -12 % |
| 2020 | 99.17 % | -26.7 % | -27.35 % |
| 2019 | 98.48 % | -116.53 % | -112.82 % |
| 2018 | 99.33 % | -163.37 % | -158.43 % |
| 2017 | 93.92 % | -1,768.89 % | -1,733.33 % |
| 2016 | 93.92 % | -315.69 % | -339.22 % |
| 2015 | 93.92 % | -178.89 % | -178.2 % |
| 2014 | 93.92 % | -986.75 % | -1,095.18 % |
| 2013 | 93.92 % | -1,219.44 % | -1,236.11 % |
| 2012 | 93.92 % | -4,321.74 % | -4,295.65 % |
| 2011 | 93.92 % | -1,800 % | -1,791.67 % |
| 2010 | 93.92 % | 28.24 % | 30.32 % |
| 2009 | 93.92 % | -13,862.5 % | -13,937.5 % |
| 2008 | 93.92 % | 0 % | 0 % |
| 2007 | 93.92 % | -630.95 % | -589.68 % |
| 2006 | 93.92 % | -128.36 % | -112.24 % |
| 2005 | 93.92 % | -290.3 % | -274.55 % |
| 2004 | 93.92 % | -1,210.64 % | -1,197.87 % |
| components_charts_MarginsChart_15 | components_charts_MarginsChart_17 | components_charts_MarginsChart_16 | |
|---|---|---|---|
| 2004 | 93.92 % | -1,210.64 % | -1,197.87 % |
| 2005 | 93.92 % | -290.3 % | -274.55 % |
| 2006 | 93.92 % | -128.36 % | -112.24 % |
| 2007 | 93.92 % | -630.95 % | -589.68 % |
| 2008 | 93.92 % | 0 % | 0 % |
| 2009 | 93.92 % | -13,862.5 % | -13,937.5 % |
| 2010 | 93.92 % | 28.24 % | 30.32 % |
| 2011 | 93.92 % | -1,800 % | -1,791.67 % |
| 2012 | 93.92 % | -4,321.74 % | -4,295.65 % |
| 2013 | 93.92 % | -1,219.44 % | -1,236.11 % |
| 2014 | 93.92 % | -986.75 % | -1,095.18 % |
| 2015 | 93.92 % | -178.89 % | -178.2 % |
| 2016 | 93.92 % | -315.69 % | -339.22 % |
| 2017 | 93.92 % | -1,768.89 % | -1,733.33 % |
| 2018 | 99.33 % | -163.37 % | -158.43 % |
| 2019 | 98.48 % | -116.53 % | -112.82 % |
| 2020 | 99.17 % | -26.7 % | -27.35 % |
| 2021 | 99.33 % | -6.03 % | -12 % |
| 2022 | 98.59 % | -45.17 % | -48.75 % |
| 2023 | 93.92 % | -17.53 % | -21.47 % |
| 2024e | 93.92 % | -5.87 % | -7.55 % |
| 2025e | 93.92 % | 9.34 % | 7.8 % |
| 2026e | 93.92 % | 20.8 % | 18.1 % |
| 2027e | 93.92 % | 26.72 % | 23.51 % |
| 2028e | 93.92 % | 31.24 % | 24.28 % |
| 2029e | 93.92 % | 35.49 % | 26.16 % |
| 2030e | 93.92 % | 37.16 % | 20.26 % |
| components_charts_RevenuePerShareChart_17 | Rigel Pharmaceuticals components_charts_RevenuePerShareChart_10 | Rigel Pharmaceuticals components_charts_RevenuePerShareChart_12 | Rigel Pharmaceuticals components_charts_RevenuePerShareChart_11 |
|---|---|---|---|
| 2030e | 2.06 undefined | 0 undefined | 0.42 undefined |
| 2029e | 1.85 undefined | 0 undefined | 0.48 undefined |
| 2028e | 1.68 undefined | 0 undefined | 0.41 undefined |
| 2027e | 1.5 undefined | 0 undefined | 0.35 undefined |
| 2026e | 1.33 undefined | 0 undefined | 0.24 undefined |
| 2025e | 1.12 undefined | 0 undefined | 0.09 undefined |
| 2024e | 0.87 undefined | 0 undefined | -0.07 undefined |
| 2023 | 0.67 undefined | -0.12 undefined | -0.14 undefined |
| 2022 | 0.7 undefined | -0.31 undefined | -0.34 undefined |
| 2021 | 0.88 undefined | -0.05 undefined | -0.1 undefined |
| 2020 | 0.64 undefined | -0.17 undefined | -0.18 undefined |
| 2019 | 0.35 undefined | -0.41 undefined | -0.4 undefined |
| 2018 | 0.28 undefined | -0.45 undefined | -0.44 undefined |
| 2017 | 0.04 undefined | -0.63 undefined | -0.62 undefined |
| 2016 | 0.22 undefined | -0.68 undefined | -0.73 undefined |
| 2015 | 0.33 undefined | -0.58 undefined | -0.58 undefined |
| 2014 | 0.09 undefined | -0.93 undefined | -1.04 undefined |
| 2013 | 0.08 undefined | -1.01 undefined | -1.02 undefined |
| 2012 | 0.03 undefined | -1.33 undefined | -1.32 undefined |
| 2011 | 0.08 undefined | -1.36 undefined | -1.36 undefined |
| 2010 | 2.38 undefined | 0.67 undefined | 0.72 undefined |
| 2009 | 0.02 undefined | -2.71 undefined | -2.73 undefined |
| 2008 | 0 undefined | -3.8 undefined | -3.68 undefined |
| 2007 | 0.44 undefined | -2.75 undefined | -2.57 undefined |
| 2006 | 1.35 undefined | -1.73 undefined | -1.51 undefined |
| 2005 | 0.75 undefined | -2.19 undefined | -2.07 undefined |
| 2004 | 0.26 undefined | -3.14 undefined | -3.11 undefined |
| components_charts_RevenuePerShareChart_10 | components_charts_RevenuePerShareChart_12 | components_charts_RevenuePerShareChart_11 | |
|---|---|---|---|
| 2004 | 0.26 USD | -3.14 USD | -3.11 USD |
| 2005 | 0.75 USD | -2.19 USD | -2.07 USD |
| 2006 | 1.35 USD | -1.73 USD | -1.51 USD |
| 2007 | 0.44 USD | -2.75 USD | -2.57 USD |
| 2008 | 0 USD | -3.8 USD | -3.68 USD |
| 2009 | 0.02 USD | -2.71 USD | -2.73 USD |
| 2010 | 2.38 USD | 0.67 USD | 0.72 USD |
| 2011 | 0.08 USD | -1.36 USD | -1.36 USD |
| 2012 | 0.03 USD | -1.33 USD | -1.32 USD |
| 2013 | 0.08 USD | -1.01 USD | -1.02 USD |
| 2014 | 0.09 USD | -0.93 USD | -1.04 USD |
| 2015 | 0.33 USD | -0.58 USD | -0.58 USD |
| 2016 | 0.22 USD | -0.68 USD | -0.73 USD |
| 2017 | 0.04 USD | -0.63 USD | -0.62 USD |
| 2018 | 0.28 USD | -0.45 USD | -0.44 USD |
| 2019 | 0.35 USD | -0.41 USD | -0.4 USD |
| 2020 | 0.64 USD | -0.17 USD | -0.18 USD |
| 2021 | 0.88 USD | -0.05 USD | -0.1 USD |
| 2022 | 0.7 USD | -0.31 USD | -0.34 USD |
| 2023 | 0.67 USD | -0.12 USD | -0.14 USD |
| 2024e | 0.87 USD | 0 USD | -0.07 USD |
| 2025e | 1.12 USD | 0 USD | 0.09 USD |
| 2026e | 1.33 USD | 0 USD | 0.24 USD |
| 2027e | 1.5 USD | 0 USD | 0.35 USD |
| 2028e | 1.68 USD | 0 USD | 0.41 USD |
| 2029e | 1.85 USD | 0 USD | 0.48 USD |
| 2030e | 2.06 USD | 0 USD | 0.42 USD |
| components_EarningsSuprises__1 | components_EarningsSuprises__2 | components_EarningsSuprises__3 | components_EarningsSuprises__4 |
|---|---|---|---|
| 3/31/2024 | -0.03 | -0.05 (-70.07 %) | 2024 Q1 |
| 12/31/2023 | -0.03 | 0 (100 %) | 2023 Q4 |
| 9/30/2023 | -0.07 | -0.03 (58.56 %) | 2023 Q3 |
| 6/30/2023 | -0.08 | -0.04 (49.75 %) | 2023 Q2 |
| 3/31/2023 | -0.1 | -0.08 (19.6 %) | 2023 Q1 |
| 12/31/2022 | -0.11 | 0.01 (108.74 %) | 2022 Q4 |
| 9/30/2022 | -0.14 | -0.11 (19.77 %) | 2022 Q3 |
| 6/30/2022 | -0.13 | -0.08 (36.1 %) | 2022 Q2 |
| 3/31/2022 | -0.14 | -0.16 (-14.29 %) | 2022 Q1 |
| 12/31/2021 | -0.13 | -0.13 (0.15 %) | 2021 Q4 |
components_ESGRating_35 | — |
components_ESGRating_36 | — |
components_ESGRating_37 | — |
components_ESGRating_38 | — |
| components_ESGRating_11 | ✅ |
| components_ESGRating_39 | ❌ |
| components_ESGRating_47 | ❌ |
| components_ESGRating_24 | ✅ |
| components_ESGRating_42 | — |
| components_ESGRating_49 | — |
| components_ESGRating_48 | — |
| components_ESGRating_50 | ❌ |
| components_ESGRating_44 | ❌ |
| components_ESGRating_8 | — |
| components_ESGRating_12 | — |
| components_ESGRating_13 | ❌ |
| components_ESGRating_16 | ❌ |
| components_ESGRating_17 | ❌ |
| components_ESGRating_18 | ❌ |
| components_ESGRating_19 | ✅ |
| components_ESGRating_20 | — |
| components_ESGRating_21 | — |
| components_ESGRating_25 | — |
| components_ESGRating_26 | — |
| components_ESGRating_29 | — |
| components_ESGRating_30 | — |
| components_ESGRating_27 | — |
| components_ESGRating_28 | — |
| components_ESGRating_31 | — |
| components_ESGRating_32 | — |
| components_ESGRating_22 | ❌ |
| components_ESGRating_23 | ❌ |
| components_ESGRating_51 | — |
| components_ESGRating_41 | ❌ |
| components_ESGRating_43 | ❌ |
| components_ESGRating_46 | ❌ |
| components_ESGRating_9 | ❌ |
| components_ESGRating_10 | — |
| components_ESGRating_15 | ✅ |
| components_ESGRating_33 | ✅ |
| components_ESGRating_40 | ❌ |
| components_ESGRating_34 | ❌ |
| components_ESGRating_45 | ❌ |
| components_ESGRating_14 | ❌ |
components_ESGRating_4 components_ESGRating_52 components_ESGRating_5
components_OwnershipTable__4 | components_OwnershipTable__0 | components_OwnershipTable__1 | components_OwnershipTable__2 | components_OwnershipTable__3 |
|---|---|---|---|---|
| 9.75 % | Armistice Capital LLC | 17,100,000 | -36,000 | 12/31/2023 |
| 8.22 % | Morgan Stanley & Co. LLC | 14,411,565 | 7,467,110 | 12/31/2023 |
| 7.34 % | BlackRock Institutional Trust Company, N.A. | 12,870,331 | 888,322 | 12/31/2023 |
| 5.38 % | Soleus Capital Management, L.P. | 9,442,579 | -5,360,436 | 12/31/2023 |
| 5.10 % | The Vanguard Group, Inc. | 8,953,217 | 85,467 | 12/31/2023 |
| 2.63 % | Acadian Asset Management LLC | 4,621,764 | -38,976 | 12/31/2023 |
| 2.11 % | Geode Capital Management, L.L.C. | 3,692,699 | 145,599 | 12/31/2023 |
| 2.04 % | State Street Global Advisors (US) | 3,580,077 | 76,387 | 12/31/2023 |
| 1.58 % | Jacobs Levy Equity Management, Inc. | 2,773,564 | -722,904 | 12/31/2023 |
| 1.40 % | Nuveen LLC | 2,457,278 | 0 | 12/31/2023 |
Rigel Pharmaceuticals Inc代表的是创新、合作和患者关怀的价值观和企业理念。作为一家专注于生物技术研发的公司，Rigel Pharmaceuticals Inc以研发创新药物来满足患者需要为使命，并秉承合作精神与其他企业和研究机构合作，共同推动医疗科技的进步。该公司致力于为世界各地的患者提供安全有效的治疗方案，改善患者的生活质量。Rigel Pharmaceuticals Inc以科学、道德和透明度为基础，追求研发和创新的最佳实践，致力于为社会和健康产业的可持续发展做出贡献。
Rigel Pharmaceuticals Inc主要存在于美国。
目前，Rigel Pharmaceuticals Inc已经达到了一些重要的里程碑。其中包括： 首先，该公司的药物设计和研发实力得到了广泛的认可。他们专注于开发创新的抗炎药物，并在相关领域取得了重要的突破。 其次，Rigel Pharmaceuticals Inc的某些药物候选已经进入了临床试验阶段。这表明该公司在研究和开发方面取得了显著进展，并有望为患者提供更好的治疗选择。 此外，Rigel Pharmaceuticals Inc还取得了一些与行业伙伴的重要合作。这些合作关系有助于推动其研发项目的进展，并为未来的商业化铺平道路。 总之，Rigel Pharmaceuticals Inc在药物研发领域取得了重要的里程碑，表明他们具备强大的实力和潜力。
Rigel Pharmaceuticals Inc是一家生物制药公司，总部位于美国加利福尼亚州。该公司专注于研发和商业化小分子药物，以满足免疫系统及代谢性疾病患者的需求。成立于1996年，Rigel Pharmaceuticals Inc致力于创新且高效的药物研究开发，以改善患者的生活质量。该公司的主力药物包括Tavalisse（fostamatinib disodium），用于治疗特发性血小板减少性紫癜（ITP）。作为一家全球领先的生物制药公司之一，Rigel Pharmaceuticals Inc继续致力于为不同疾病患者提供创新的治疗方案。
Rigel Pharmaceuticals Inc在市场上的主要竞争对手是Eli Lilly and Company (伊利莎丽制药公司)。该公司是一家全球知名的制药公司，主要从事创新药品的研发和销售。与Rigel Pharmaceuticals Inc相比，Eli Lilly and Company拥有更广泛的产品线和更大的市场份额。作为竞争对手，两家公司在研发创新药品、市场推广策略和国际市场扩展方面都展开了激烈竞争。
Rigel Pharmaceuticals Inc主要从事生物技术和制药行业。作为一家创新型的生物技术公司，Rigel Pharmaceuticals Inc致力于研发和商业化先进的疾病治疗方案。该公司专注于发现、开发和销售创新的小分子药物，旨在满足全球患者对于多种严重疾病的医疗需求。Rigel Pharmaceuticals Inc的产品和疗法主要针对免疫性、炎症性和癌症等疾病领域，为患者提供更好的治疗选择。通过不断的创新和卓越的研发实力，Rigel Pharmaceuticals Inc在生物技术和制药领域取得了显著的成就。
Rigel Pharmaceuticals Inc的商业模式着重于研发和销售创新的生物技术药物。作为一家生物医药公司，Rigel Pharmaceuticals Inc专注于发现、开发和商业化治疗罕见疾病的新药物。该公司拥有多项专利技术和独特的药物开发平台，通过与合作伙伴合作，加速新药物的开发进程。Rigel Pharmaceuticals Inc致力于满足患者需求，并为医疗保健行业提供创新解决方案。通过不断推动科学研究和临床试验，该公司致力于改善人们的生活质量，并为股东创造长期价值。
pages_aktie_[isin]__12
pages_aktie_[isin]__15
pages_aktie_[isin]__18
pages_aktie_[isin]__21
pages_aktie_[isin]__24
pages_aktie_[isin]__27
pages_aktie_[isin]__30
pages_aktie_[isin]__34
pages_aktie_[isin]__36
pages_aktie_[isin]__38
pages_aktie_[isin]__40
pages_aktie_[isin]_[key]_index_1
pages_aktie_[isin]_[key]_index_3
pages_aktie_[isin]_[key]_index_5
pages_aktie_[isin]_[key]_index_7
pages_aktie_[isin]_[key]_index_9
pages_aktie_[isin]_[key]_index_14
pages_aktie_[isin]_[key]_index_15
pages_aktie_[isin]_[key]_index_18
pages_aktie_[isin]_[key]_index_20
pages_aktie_[isin]_[key]_index_22
components_Profile_KeyStats__40
components_Profile_KeyStats__33
components_Profile_KeyStats__36
components_Profile_KeyStats__37| components_Profile_Tickers_1 | Rigel Pharmaceuticals components_Profile_Tickers_2 |
|---|---|
| COMPONENTS_PROFILE_TICKERS_25 | RI2A.DU |
| COMPONENTS_PROFILE_TICKERS_23 | RI2A.F |
| COMPONENTS_PROFILE_TICKERS_13 | RI2A.MU |
| NASDAQ | RIGL |
| SIX | RI2A.SW |
| Rigel Pharmaceuticals components_Profile_Tickers_2 | Rigel Pharmaceuticals FIGI |
|---|---|
| RI2A:GR | BBG000BKZNC0 |
| RI2A:GF | BBG000BKZNR4 |
| RI2A:GD | BBG000BKZNX7 |
| RI2A:GS | BBG000BKZQB4 |
| RI2A:GM | BBG000BKZQJ6 |
| RI2A:GB | BBG000BKZQX0 |
| RIGL:US | BBG000BPWTW7 |
| RIGL:UA | BBG000BPWVL4 |
| RIGL:UC | BBG000BPWVT6 |
| RIGL:UN | BBG000BPWWL2 |
| RIGL:UP | BBG000BPWWR6 |
| RIGL:UB | BBG000BPWXD9 |
| RIGL:UM | BBG000BPWY01 |
| RIGL:UX | BBG000BPWZ53 |
| RIGL:UD | BBG000BPX184 |
| RIGL:UW | BBG000BPX2D6 |
| RIGL:UF | BBG000BPX317 |
| RIGL:VY | BBG000BPX3C5 |
| RIGL:VJ | BBG000BPX3Q0 |
| RIGL:VK | BBG000BPX424 |
| RIGL:VF | BBG00DJF74K9 |
| RIGLUSD:X2 | BBG00JR8G8G9 |
| RIGLUSD:XB | BBG00JR8G8H8 |
| RIGLUSD:XH | BBG00JR8G8K4 |
| RIGLUSD:XF | BBG00JR8G8M2 |
| RIGLUSD:XE | BBG00JR8G8P9 |
| RIGLUSD:XJ | BBG00JR8G8Q8 |
| RIGLUSD:XL | BBG00JR8G8R7 |
| RIGLUSD:XG | BBG00JR8G8S6 |
| RIGLUSD:XO | BBG00JR8G8T5 |
| RIGLUSD:XS | BBG00JR8G8Y9 |
| RIGLUSD:XA | BBG00JR8G8Z8 |
| RIGLUSD:E1 | BBG00JR8G904 |
| RIGLUSD:XT | BBG00JR8G913 |
| RIGLUSD:XW | BBG00JR8G922 |
| RIGLUSD:XU | BBG00JR8G931 |
| RIGLUSD:XV | BBG00JR8G940 |
| RIGLUSD:XM | BBG00JR8G959 |
| RIGLUSD:XQ | BBG00JR8G977 |
| RIGLUSD:XX | BBG00JR8G986 |
| RIGLUSD:XZ | BBG00JR8G995 |
| RIGLUSD:EU | BBG00JR8G9C1 |
| RIGLEUR:X2 | BBG00JVK2PR2 |
| RIGLEUR:XB | BBG00JVK2PS1 |
| RIGLEUR:XH | BBG00JVK2PV7 |
| RIGLEUR:XF | BBG00JVK2PX5 |
| RIGLEUR:XE | BBG00JVK2PZ3 |
| RIGLEUR:XJ | BBG00JVK2Q09 |
| RIGLEUR:XL | BBG00JVK2Q18 |
| RIGLEUR:XG | BBG00JVK2Q27 |
| RIGLEUR:XO | BBG00JVK2Q36 |
| RIGLEUR:XS | BBG00JVK2Q72 |
| RIGLEUR:XA | BBG00JVK2Q81 |
| RIGLEUR:E1 | BBG00JVK2Q90 |
| RIGLEUR:XT | BBG00JVK2QB7 |
| RIGLEUR:XW | BBG00JVK2QC6 |
| RIGLEUR:XU | BBG00JVK2QD5 |
| RIGLEUR:XV | BBG00JVK2QF3 |
| RIGLEUR:XM | BBG00JVK2QG2 |
| RIGLEUR:XQ | BBG00JVK2QJ9 |
| RIGLEUR:XX | BBG00JVK2QK7 |
| RIGLEUR:XZ | BBG00JVK2QL6 |
| RIGLEUR:EU | BBG00JVK2QN4 |
| RIGLGBP:XS | BBG00KTNKGM1 |
| RIGLGBP:XH | BBG00KTNKGQ7 |
| RIGLGBP:XF | BBG00KTNKGS5 |
| RIGLGBP:XE | BBG00KTNKGV1 |
| RIGLGBP:XJ | BBG00KTNKGW0 |
| RIGLGBP:XL | BBG00KTNKGX9 |
| RIGLGBP:XG | BBG00KTNKGY8 |
| RIGLGBP:XO | BBG00KTNKGZ7 |
| RIGLGBP:XA | BBG00KTNKH30 |
| RIGLGBP:E1 | BBG00KTNKH49 |
| RIGLGBP:XT | BBG00KTNKH58 |
| RIGLGBP:XW | BBG00KTNKH67 |
| RIGLGBP:XU | BBG00KTNKH76 |
| RIGLGBP:XV | BBG00KTNKH85 |
| RIGLGBP:XM | BBG00KTNKH94 |
| RIGLGBP:XQ | BBG00KTNKHC0 |
| RIGLGBP:XX | BBG00KTNKHD9 |
| RIGLGBP:XZ | BBG00KTNKHF7 |
| RIGLGBP:EU | BBG00KTNKHH5 |
| RI2A:SW | BBG00LVG9RM0 |
| RI2A:BW | BBG00LVG9RT3 |
| RI2A:TH | BBG00QKCL161 |
| RI2A:QT | BBG00QKHTQ76 |
| RIGLEUR:EP | BBG00QKK1FX4 |
| RIGLEUR:EZ | BBG00QKK1G08 |
| RIGLUSD:EP | BBG00R2MMBP3 |
| RIGLUSD:EZ | BBG00R2MMBR1 |
| RI2A:GZ | BBG00WC6TL77 |
| RIGL:VG | BBG00X1MK139 |
| RIGL:VP | BBG00X1QZKJ5 |
| RI2A:LA | BBG018H7QYT3 |
| RI2A:LU | BBG018J1D1G4 |
components_SimilarSitesList_0
components_GenericText_2
components_GenericText_3
components_GenericText_4
components_GenericText_6
components_GenericText_8
components_GenericText_9
components_GenericText_11
components_GenericText_13
components_GenericText_14
components_GenericText_17
components_GenericText_19
components_GenericText_21
components_GenericText_23
components_GenericText_25
components_GenericText_26
components_GenericText_29
components_GenericText_31
components_GenericText_33
components_GenericText_34
components_GenericText_36
components_GenericText_38
components_GenericText_39
components_GenericText_42
components_GenericText_44
components_GenericText_46
components_GenericText_48
components_GenericText_50
components_GenericText_52
components_GenericText_53
components_GenericText_55
components_GenericText_57
components_GenericText_59
components_GenericText_61
components_GenericText_63
components_GenericText_65
components_GenericText_66
components_GenericText_68
components_GenericText_70
components_GenericText_72
components_GenericText_74
components_GenericText_76
components_GenericText_78
components_GenericText_79
components_GenericText_81
components_GenericText_83
components_GenericText_85
components_GenericText_87
components_GenericText_89
components_GenericText_91
components_GenericText_92
components_GenericText_94
components_GenericText_96
components_GenericText_98
components_GenericText_100
components_GenericText_102
components_GenericText_104
components_GenericText_106
components_GenericText_108
components_GenericText_109
components_GenericText_111
components_GenericText_113
components_GenericText_115
components_GenericText_117
components_GenericText_119
components_GenericText_121
components_GenericText_123
components_GenericText_125
components_GenericText_127
components_GenericText_129
components_GenericText_131
components_GenericText_133
components_GenericText_134
components_GenericText_136
components_GenericText_157
components_GenericText_159
components_GenericText_160
components_GenericText_162
components_GenericText_177
components_GenericText_179
components_GenericText_181
components_GenericText_183
components_GenericText_184
components_GenericText_186
components_GenericText_187
components_GenericText_189
components_GenericText_191
components_GenericText_193
components_GenericText_195
components_GenericText_197
components_GenericText_198
components_GenericText_201
components_GenericText_202
components_GenericText_205components_GenericText_204
components_GenericText_207components_GenericText_206
components_GenericText_208components_GenericText_209
components_GenericText_211components_GenericText_212
components_GenericText_213components_GenericText_214
components_GenericText_215components_GenericText_216
components_GenericText_219components_GenericText_218
components_GenericText_220components_GenericText_221
components_GenericText_222components_GenericText_223
components_GenericText_224
components_GenericText_225
components_GenericText_228
components_GenericText_229
components_GenericText_231
components_GenericText_233
components_GenericText_235
components_GenericText_237
components_GenericText_239
components_GenericText_240
components_GenericText_241
components_GenericText_243
components_GenericText_244
components_GenericText_246
components_GenericText_249
components_GenericText_251
components_GenericText_253
components_GenericText_254
components_GenericText_256
components_GenericText_257
components_GenericText_259
components_GenericText_261
components_GenericText_263
components_GenericText_265
components_GenericText_267
components_GenericText_269
components_GenericText_270
components_GenericText_273 components_GenericText_274:
components_GenericText_290 components_GenericText_291:
components_GenericText_301
components_Profile_KeyStats__35
